Highlights
- •This was an analysis of treatment decisions based on genetic mutations in breast cancer.
- •The study was a retrospective review.
- •There was a higher than expected percentage of risk reduction surgery in the mutation of unknown clinical significance.
- •Patients in the Pacific Northwest chose radiographic surveillance over surgery more than other regions.
- •Surgeons must help patients understand the difference between pathogenic mutations and variants of unknown significance.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Published online: February 15, 2018
Accepted:
November 22,
2017
Received:
November 22,
2017
Identification
Copyright
Published by Elsevier Inc.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Risk management decisions in women with BRCA1 and BRCA2 mutationsThe American Journal of SurgeryVol. 215Issue 5
